Table 1 Baseline characteristics of patients at treatment initiation by study period
Variable | 2011–2014 (n = 1495) | 2015–2017 Feb (n = 1524) | P |
|---|---|---|---|
N(%) | N(%) | ||
Male Sex | 1242 (83.1) | 1363 (89.4) | < 0.001 |
Age | |||
Median (IQR), years | 37 (29–46) | 34 (27–45) | < 0.001 |
HIV-RNA load | |||
Median (IQR), log10 copies/mL | 5.1 (4.6–5.6) | 5.1 (4.5–5.7) | 0.590 |
Pretreatment CD4 + cell count | |||
Median (IQR), cells/µL | 325 (166–470) | 365 (222–520) | < 0.001 |
Transmission mode | |||
MSM/Bisexual | 459 (30.7) | 579 (38.0) | 0.001 |
Heterosexual | 880 (58.9) | 803 (52.7) | |
IDU | 2 (0.1) | 4 (0.3) | |
Other | 36 (2.4) | 26 (1.7) | |
Unknown | 118 (7.9) | 112 (7.3) | |
Lost to follow up | 67 (4.5%) | 55 (3.6%) | 0.277 |
Drug Class | |||
InSTI | 24 (1.6) | 1111 (72.9) | < 0.001 |
NNRTI | 726 (48.6) | 72 (4.7) | |
PI | 744 (49.8) | 336 (22.0) | |
InSTI/PI | 1 (0.1) | 5 (0.3) | |
Regimen | |||
EFV/TDF/FTC | 678 (45.4) | 72 (4.7) | < 0.001 |
LPV/r/TDF/FTC | 565 (37.8) | 178 (11.7) | |
EVG/c/TDF/FTC | 5 (0.3) | 675 (44.3) | |
DTG/TDF/FTC | 4 (0.3) | 347 (22.8) | |
DRV/r/TDF/FTC | 126 (8.4) | 150 (9.8) | |
RAL/TDF/FTC | 14 (0.9) | 51 (3.3) | |
LPV/r/ZDV/3TC | 47 (3.1) | 6 (0.4) | |
EFV/ZDV/3TC | 39 (2.6) | – | |
Other | 17 (1.1) | 45 (3.0) | |